hI-con1 + ranibizumab

hI-con1 + ranibizumab is a **combination therapy** evaluated in clinical trials for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). **hI-con1 (also called ICON-1)** is an immunoconjugate fusion protein that binds to **tissue factor** (TF), which is overexpressed on pathologic vessels involved in neovascular AMD, acting via a novel anti-angiogenic and anti-exudative mechanism. **Ranibizumab** is a recombinant, humanized monoclonal antibody fragment targeting **vascular endothelial growth factor A (VEGF-A)**, inhibiting VEGF-driven angiogenesis and vascular permeability. The combination is administered by **intravitreal injection** and is hypothesized to exert **synergistic effects** by inhibiting angiogenesis at multiple points in the neovascular cascade. Clinical trials (notably the EMERGE Phase 2 study) compared hI-con1 + ranibizumab to each agent as monotherapy, focusing on change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Results indicated ranibizumab alone was superior in reduction of central subfield thickness, with no significant gain in visual acuity from combination therapy versus ranibizumab monotherapy[1][2][3][4][6].

Other names

ICON-1 + ranibizumab